Arrowhead Pharmaceuticals, Inc. (FRA:HDP1)

Market Cap	7.56B +210.6%
Revenue (ttm)	929.19M +43,539.2%
Net Income	172.27M
EPS	1.26
Shares Out	n/a
PE Ratio	43.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	54.02
Previous Close	54.08
Day's Range	53.56 - 54.52
52-Week Range	8.85 - 64.14
Beta	n/a
RSI	47.01
Earnings Date	Feb 5, 2026

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 711
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HDP1

Financial Performance

In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD